PFE anounced earnings down 3.6 billion. This was due to the massive expenses in the Pharmacia-Upjohn buyout. Also Lipitor sales were down. I would still hold this stock and even consider buying more. They are getting a lot of product line from Upjohn that isn't the big $ profit of the cox 2 inhibitors. Drugs like Depo Provera (birth control in females and chemical castration in males), Depo testosterone (old fashioned Viagra), Depo Medrol (one of the last long term coricosteroids still on the market). All of these drugs are off patent, but aren't big enough money makers for a generic company to go after them. At least so far. With them spending 7B on research (just a few years ago MRK was amazing the market by spending 1B), they have to come up with some great stuff. This is a one time write off!